Company Overview of Dr. Reddy's Laboratories Limited
Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also prov...
8-2-337, Road No. 3
Founded in 1984
Key Executives for Dr. Reddy's Laboratories Limited
Co-Chairman, MD & CEO
Total Annual Compensation: 18.5M
Chairman of the Board
Total Annual Compensation: 6.3M
Compensation as of Fiscal Year 2017.
Dr. Reddy's Laboratories Limited Key Developments
Goldberg Law PC Announces Securities Class Action Lawsuit Against Dr. Reddy's Laboratories Limited
Oct 18 17
Goldberg Law PC announced the filing of a class action lawsuit against Dr. Reddy's Laboratories Limited for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The complaint alleges that during the Class Period, Dr. Reddy's made false and/or misleading statements, and/or failed to disclose, that the Company lacked an effective corporate quality system; and thus its public statements were materially false and misleading at all relevant times. On August 10, 2017, Dr. Reddy's disclosed that the Regulatory of Germany (Regierung von Oberbayern) did not renew the good manufacturing practices compliance certificate of a formulations manufacturing unit of its German subsidiary Betapharm Arzneimittel, located in Hyderabad, India, following a recent inspection of the plant. When this news was announced, shares of Dr. Reddy's fell in value materially, which caused investors harm.
Dr. Reddy's Laboratories Limited Announces Launch of Sevelamer Carbonate Tablets in U.S. Market
Sep 29 17
Dr. Reddy's Laboratories Limited announced that it has launched Sevelamer Carbonate Tablets, 800 mg, a therapeutic equivalent generic version of Renvela® (sevelamer carbonate) Tablets, approved by the U.S. Food and Drug Administration (USFDA). The Renvela brand and generic had U.S. sales of approximately $1.88 billion MAT for the most recent twelve months ending in July 2017 according to IMS Health. Dr. Reddy’s Sevelamer Carbonate Tablets, 800 mg are available in the bottle count size of 270 tablets.
Dr. Reddy's Laboratories Limited Announces Completion of Audit of API Mirfield Plant by the US FDA
Sep 15 17
Dr. Reddy's Laboratories Limited announced that the audit of API Mirfield Plant, United Kingdom, by the US FDA has been completed on September 15, 2017. The company has issues a Form 483 with three observations.
Similar Private Companies By Industry
Recent Private Companies Transactions
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries